People sending me their, or their family's, or their friends and neighbors blood investigations and scan reports on my DM, please stop. It is disrespectful. Easy approachability must not equate to trivialization of the medical profession. There is a systematic way to diagnose,

What does that all mean? You as a researcher pay to get access to your own work! You as a researcher review works of others for Elsevier journals for free! And if you want free access to your work, you pay about 1 month salary for one article! So, Non Solus (not alone)? We as

#ASH24 starts this week! Excited to attend the annual scientific extravaganza and interact with friends, colleagues, collaborators and industry at San Diego. Happy to present the following studies from MD Anderson Cancer Center at #ASH24 ➡️ Check them out if you are interested in

Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 Thanos Dimopoulos NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.10… Slides in thread

When writing treatment orders for induction therapy, frontline transplant-eligible myeloma, this is the correct box to click. No one can guarantee outcome, but you can guarantee intent. #mmsm

Donate blood, save lives! Your one act of kindness can be a lifeline for someone in need. #DonateBlood

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma | Leukemia nature.com/articles/s4137…

HLH, a cytokine-mediated hyperinflammation syndrome, causes fever, pancytopenia, and hemophagocytosis and is often fatal. Antiinflammatory agents, etoposide, and interferon-γ antibody are the main treatments. Learn more in a new review: nej.md/40Jps19

Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML ashpublications.org/blood/article/… 👉 Venetoclax plus decitabine NOT INFERIOR to intensive chemo in young fit AML. 👉VEN+DEC was well tolerated. #lesum #AML

Check out our comprehensive review on #AML from an MD Anderson Cancer Center perspective, " Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges" published in ACS Journal Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #leusm

Newly diagnosed with MM? MASTER-2 addressed response adapted therapy with the perspective of finite treatment. Accruing fast! #mmsm

AML-MP and MPAL are biologically distinct despite sharing features of MP. ow.ly/ctok50VLFRc #myeloidneoplasia

Cases of Acute Myeloid Leukaemia (AML) - a rare, fast-growing cancer of the blood and bone marrow - are rising in the 30-40 age group. Individuals previously exposed to radiation or chemotherapy may be at higher risk. A simple blood test can help detect AML early.

a comprehensive report of the survival outcomes among 240 patients who underwent a transplant at the MD Anderson Cancer Center for acute myeloid leukemia AML or myelodysplastic syndrome with TP53 mutations over a 10-year period. ow.ly/Y03x50W7qaE #transplantation

Plenary #3 #EHA2025 Very proud 🇦🇺 of Australasian Leukaemia & Lymphoma Group (ALLG) randomized CAST trial Practice-changing study showing substantial reduction in GRFS, relapse-free survival & GvHD for PTCy in matched sibling donor allogeneic transplant Out in NEJM nejm.org/doi/full/10.10… #bmtsm

CONGRESS | #18ICML | PRESENTATION Kate Cwynarski Kate Cwynarski UCLH presents 7-year follow-up results from the phase II MARIETTA trial of multi-agent chemotherapy with MATRix and R-ICE followed by TT-ASCT in patients with SCNSL (N = 75). Long-term follow-up results demonstrate

Cytomegalovirus is increasingly recognized as an important pathogen in recipients of chimeric antigen receptor T-cell therapy, yet its clinical impact remains largely unexplored. ow.ly/PKYY50WfF4q #clinicaltrialsandbservations #immunobiologyandimmunotherapy

#EstudiosColaborativos Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study | Blood Advances ashpublications.org/bloodadvances/… GELTAMO GETH

HGBCL-NOS: We identify another histology with relatively CAR resistant relapse. N=111, most axi-cel, 2 year OS and PFS 42% and 29%. NRM 3%. #lymsm #cibmtr BJH | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

I am scared of using CART or bispecifics in myeloma with large volume disease: CRS, neurotoxicity, HLH, risk of death, and all kinds of complications are much higher. I’d rather control myeloma and get it to low volume before using these immunotherapy treatments. This is why